Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with Phase 2 clinical trials for its lead multiple sclerosis (MS) candidate, Lucid-MS (Lucid-21-302). The approval of the Investigational New Drug (IND) application allows the company to move forward with a randomized, double-blind, placebo-controlled study designed to evaluate the drug’s efficacy, safety, and tolerability in people with MS, using both clinical and radiological endpoints.
This development is significant because Lucid-MS is not just another MS therapy that aims to suppress the immune system. Instead, it is a first-in-class candidate that targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. By inhibiting PAD2, Lucid-MS is designed to provide neuroprotection and potentially prevent or even reverse the demyelination that characterizes MS. Preclinical models have shown that Lucid-MS can prevent and reverse myelin breakdown, and Phase 1 trials in healthy volunteers demonstrated a favorable safety profile and good tolerability.
The advancement into Phase 2 comes at a time when the MS treatment landscape is evolving, with a growing emphasis on neuroprotection and repair rather than just reducing inflammation. Existing therapies, while effective in managing relapses, often do not address the progressive neurodegeneration that leads to long-term disability. Lucid-MS’s unique mechanism could fill that gap, offering hope for a disease-modifying approach that directly targets the underlying pathology.
Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, which is a patented new chemical entity. The company also holds a stake in Unbuzzd Wellness Inc., the maker of UNBUZZD, an over-the-counter product aimed at reducing alcohol cravings. Quantum retains a 19.84% ownership in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales until they reach $250 million, after which the royalty drops to 3% in perpetuity.
The company has reported a strong financial position with more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which could support the upcoming trial. Trial start-up activities, including site selection, are already underway, and patient enrollment is expected to begin as soon as possible.
The approval of the IND application marks a crucial step forward for Quantum BioPharma and for the MS community. If Lucid-MS proves successful in Phase 2, it could revolutionize the treatment of MS by offering a therapy that not only halts disease progression but also potentially restores lost function. This would represent a major advancement in the field, moving beyond symptomatic management to a true neurorestorative approach. Investors and patients alike will be watching closely as the trial progresses.
